Victoza · Saxenda · Once-daily GLP-1 receptor agonist
The first GLP-1 receptor agonist to gain widespread clinical adoption, and the compound that established the proof of concept that led to semaglutide and tirzepatide. FDA-approved as Victoza for type 2 diabetes and Saxenda for obesity management. Now largely superseded by more effective once-weekly alternatives, but still prescribed, still relevant, and carrying a cardiovascular outcomes trial that informed the entire drug class.
01, Research Summary
Liraglutide has one of the most extensive evidence bases of any GLP-1 drug, it was the compound on which many of the foundational GLP-1 findings were established. The LEADER cardiovascular outcomes trial (9,340 patients, 3.8 years) demonstrated a 13% reduction in major adverse cardiovascular events, establishing the cardiovascular protection signal that the entire drug class now benefits from in prescriber confidence. The SCALE trials established weight loss efficacy at the 3mg (Saxenda) dose.
13% reduction in MACE in high-risk type 2 diabetes patients. The first GLP-1 cardiovascular outcomes trial to show significant benefit, this landmark result established the class effect that informed SELECT (semaglutide) and subsequent cardiovascular trials.
~8% average body weight reduction at 3mg/day over 56 weeks. FDA basis for Saxenda approval. Significantly lower than semaglutide (~15%) or tirzepatide (~20%), reflecting both dose and mechanism differences. Meaningful but outperformed by second-generation options.
Liraglutide requires daily injection versus semaglutide's weekly or Wegovy's weekly schedule. For adherence-sensitive patients, once-daily dosing is a meaningful disadvantage. The efficacy gap versus semaglutide is also well-established, in direct comparisons, semaglutide consistently produces greater weight loss and glycaemic control. The primary remaining advantage for liraglutide is its longer track record and more established prescribing patterns in some clinical settings.
02, Mechanism of Action
Liraglutide acts as a GLP-1 receptor agonist, binding the GLP-1 receptor with high affinity to produce the same downstream effects as endogenous GLP-1: increased insulin secretion, reduced glucagon, slowed gastric emptying, and central appetite suppression via hypothalamic signalling.
Liraglutide binds GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion, insulin rises when blood sugar is high, not at baseline. This mechanism makes hypoglycaemia rare compared to sulfonylureas.
GLP-1 receptors in the hypothalamus and brainstem regulate appetite and satiety. Liraglutide activates these central receptors, producing appetite suppression and "food noise" reduction, the reduced preoccupation with food that GLP-1 users consistently report.
Slowing gastric emptying extends the feeling of fullness after meals and blunts post-meal blood sugar spikes. This mechanism drives most of the GI side effects (nausea, vomiting) that are characteristic of the drug class.
The key difference from semaglutide is potency and half-life. Liraglutide has a 13-hour half-life requiring daily dosing. Semaglutide has a ~1-week half-life achieved through albumin binding. At equivalent doses, semaglutide produces more complete receptor engagement and more sustained suppression of appetite. Tirzepatide adds the GIP receptor mechanism on top of GLP-1, producing synergistic effects that outperform both.
03, Dosing Context
Liraglutide requires daily subcutaneous injection and dose escalation over several weeks to minimise GI side effects.
| Indication | Starting dose | Maintenance dose | Escalation |
|---|---|---|---|
| Type 2 diabetes (Victoza) | 0.6mg/day | 1.2–1.8mg/day | Weekly escalation by 0.6mg |
| Obesity (Saxenda) | 0.6mg/day | 3mg/day | Weekly escalation by 0.6mg to 3mg |
Side effect profile mirrors the drug class: nausea (most common, typically resolves 4–8 weeks), vomiting, diarrhoea, constipation. The risk of pancreatitis and gallbladder disease applies. Thyroid C-cell tumour risk is a class warning (rodent data, not confirmed in humans at clinical doses) but Saxenda is contraindicated in patients with personal/family history of medullary thyroid carcinoma.
04, Community
Community discussion of liraglutide is largely retrospective, patients who used Saxenda before semaglutide and tirzepatide became available, comparing their experience to the newer drugs. The consensus is that liraglutide produces real but more modest results, with the daily injection burden as the primary practical complaint. For patients who tried Saxenda and didn't respond adequately, semaglutide or tirzepatide is almost universally the recommendation for next steps.